Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.
Volition's major achievements in 2023 include:
To find out more about these achievements, please read Volition's Business Review here or watch the video below.
Video - https://www.youtube.com/watch?v=YF_DAUp45Sc
Cameron Reynolds, President and Group Chief Executive Officer, said: "At Volition, we are dedicated to saving lives and improving outcomes for people and animals worldwide through our novel epigenetics platform.
"We believe we made great progress in our mission throughout 2023 and have in place compelling plans to move forward in 2024."
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition's technology go to: www.volition.com
Posted In: VNRX